Twist, Serimmune identify SARS-CoV-2 antibody therapies

By The Science Advisory Board staff writers

June 9, 2020 -- Twist Bioscience has joined forces with Serimmune to identify and evaluate SARS-CoV-2 therapeutic antibody candidates.

Existing Twist antibody candidates that bind with high affinity to either the SARS-CoV-2 S1 spike protein or the human angiotensin-converting enzyme 2 (ACE2) cellular receptor will be evaluated using Serimmune's Serum Epitope Repertoire Analysis (SERA) platforms. Those epitopes that are identified in the first phase of the collaboration will then be used to rescreen Twist's proprietary synthetic antibody discovery libraries to identify and evaluate new candidates, while also further increasing the specificity of antibody candidates, according to the companies.

Copyright © 2020

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for

Email Preferences

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.